Evaluating a new test to predict how well advanced lung cancer patients respond to anti-PD-1 therapy
Analytic and Clinical Validation of a 7-plex MIF Assay for Predictive Response of Advanced NSCLC to Anti-PD-1 based Therapy
['FUNDING_OTHER'] · JOHNS HOPKINS UNIVERSITY · NIH-10705736
This study is testing a new way to look at certain markers in your lung cancer cells to help doctors better understand how well you might respond to a specific treatment, so they can tailor your care just for you.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-10705736 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new multiplex immunofluorescence assay that can better predict the response of patients with advanced non-small cell lung cancer (NSCLC) to anti-PD-1 therapy. By analyzing various biomarkers and their interactions, including PD-L1 and PD-1 expression, the study aims to improve the accuracy of patient selection for this treatment. The assay captures multiple cellular features and spatial relationships that are not currently assessed, potentially leading to more personalized treatment approaches. Patients may have biopsies taken to evaluate these biomarkers and their expression patterns.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced non-small cell lung cancer who are being considered for anti-PD-1 therapy.
Not a fit: Patients with early-stage lung cancer or those not eligible for anti-PD-1 therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate predictions of treatment responses, allowing for better-targeted therapies for patients with advanced lung cancer.
How similar studies have performed: Previous research has shown that improving biomarker assessment can enhance treatment outcomes, suggesting that this approach may yield significant advancements.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TAUBE, JANIS M. — JOHNS HOPKINS UNIVERSITY
- Study coordinator: TAUBE, JANIS M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.